BARCELONA, Spain , Sept. 16, 2024 /PRNewswire/ -- WestGene Biopharma, a leading innovator in mRNA therapeutics, presented the latest clinical data for its EBV-positive tumour mRNA vaccine, WGc-043, during a mini-oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024. Pioneering Advances in mRNA Therapeutics WGc-043, the world's first mRNA therapeutic vaccine targeting EBV-positive tumors to achieve IND approval in both China and the US, demonstrated exceptional safety, immunogenicity, and anti-tumor activity in the latest clinical trials.
The vaccine is being developed specifically for adult patients with advanced EBV-positive solid tumours and refractory or relapsed EBV-positive lymphomas, diseases for which there are currently no effective, low-toxicity treatment options. Impressive Clinical Performance Recognized by ESMO Interim clinical data presented at ESMO 2024 highlighted the vaccine's ability to activate the patient's immune system, leading to the production of cytotoxic T cells, antigen-specific antibodies and memory T cells that target and destroy cancer cells. This novel mechanism offers a promising alternative to conventional CAR-T and monoclonal antibody therapies and also aims to prevent tumor recurrence, providing a triple benefit, particularly for patients with late-stage nasopharyngeal carcinoma and NK/T cell lymphoma.
Innovative Technology and Global Impact WGc-043 is a testament to WestGene's proprietary mRNA platform, which in.